NYSE:MED Medifast (MED) Stock Price, News & Analysis $12.04 +0.09 (+0.71%) As of 10:49 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Medifast Stock (NYSE:MED) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medifast alerts:Sign Up Key Stats Today's Range$11.94▼$12.0650-Day Range$9.44▼$13.1252-Week Range$9.22▼$14.67Volume16,309 shsAverage Volume218,477 shsMarket Capitalization$134.66 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingReduce Company Overview Medifast, Inc. (NYSE: MED) is a health and wellness company that provides weight-management and healthy-lifestyle products and programs. Its principal brand is OPTAVIA, which offers structured plans designed to support weight loss, nutrition, and long-term habit development. The company’s product portfolio includes meal-replacement shakes, bars, snacks, entrees, beverages, supplements, and other packaged “Fuelings.” Medifast also supports customers through independent OPTAVIA Coaches, who provide guidance, accountability, and lifestyle support through the company’s direct-selling model. Founded in 1980, Medifast serves customers primarily in the United States through its e-commerce and direct-to-consumer channels. The company has evolved from offering physician-directed weight-loss products into a broader wellness business centered on OPTAVIA’s integrated products, programs, and coaching services.AI Generated. May Contain Errors. Read More Medifast Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreMED MarketRank™: Medifast scored higher than 19% of companies evaluated by MarketBeat, and ranked 152nd out of 174 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingReduce Consensus RatingMedifast has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Medifast is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageMedifast has only been the subject of 2 research reports in the past 90 days.Read more about Medifast's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Medifast are expected to grow in the coming year, from ($1.04) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMedifast has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Medifast's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.49% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 15.11, which indicates bearish sentiment.Change versus previous monthShort interest in Medifast has recently increased by 3.22%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment0.34 News SentimentMedifast has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Medifast this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,423,576.00 in company stock, which represents 1.0629% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,423,576.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders3.70% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medifast's insider trading history. Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MED Stock News HeadlinesMedifast (NYSE:MED) Shares Pass Above 200 Day Moving Average - Here's WhySeptember 15 at 2:03 AM | americanbankingnews.comOcius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content UpdateSeptember 2, 2026 | prnewswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 17 at 1:00 AM | The Oxford Club (Ad)Medifast (NYSE:MED) Director Parsa Kiai Buys 43,150 SharesAugust 29, 2026 | insidertrades.comMedifast Insider Makes Bold Move With Major Share PurchaseAugust 28, 2026 | tipranks.comMedifast® Announces the Launch of the Medifast Metabolic Health Institute™August 27, 2026 | businesswire.comMedifast (NYSE:MED) Director Parsa Kiai Buys 4,329 Shares of StockAugust 27, 2026 | insidertrades.comInsider Buying: Medifast (NYSE:MED) Director Buys $342,069.42 in StockAugust 22, 2026 | insidertrades.comSee More Headlines MED Stock Analysis - Frequently Asked Questions How have MED shares performed this year? Medifast's stock was trading at $10.66 at the beginning of 2026. Since then, MED stock has increased by 12.4% and is now trading at $11.98. How were Medifast's earnings last quarter? Medifast Inc (NYSE:MED) posted its quarterly earnings results on Monday, August, 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.37. The specialty retailer earned $76.38 million during the quarter, compared to analyst estimates of $72.70 million. Medifast had a negative trailing twelve-month return on equity of 6.69% and a negative net margin of 8.08%. Read the conference call transcript. Who are Medifast's major shareholders? Medifast's top institutional investors include Steamboat Capital Partners LLC (6.32%), BlackRock Inc. (3.30%), Bank of America Corp DE (0.78%) and Empowered Funds LLC (0.59%). Insiders that own company stock include Parsa Kiai, Scott Schlackman, Daniel R Chard, Andrea B Thomas, Jeffrey J Brown and Constance J Hallquist. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY). Company Calendar Last Earnings8/03/2026Today9/17/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MED's financial health is in the Green zone, according to TradeSmith. MED has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Personal Care Products Sub-IndustryPersonal Care Products Current SymbolNYSE:MED CIK910329 Webwww.medifastinc.com Phone(410) 581-8042Fax410-581-8070Employees380Year Founded1981Price Target and Rating Average Price Target for Medifast$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside-0.3%Consensus RatingReduce Rating Score (0-4)1.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.67 million Net Margins-8.08% Pretax Margin-4.41% Return on Equity-6.69% Return on Assets-5.25% Debt Debt-to-Equity RatioN/A Current Ratio4.86 Quick Ratio4.35 Sales & Book Value Annual Sales$385.79 million Price / Sales0.35 Cash Flow$0.42 per share Price / Cash Flow28.89 Book Value$18.10 per share Price / Book0.67Miscellaneous Outstanding Shares11,180,000Free Float10,767,000Market Cap$134.61 million OptionableOptionable Beta0.71 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:MED) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Medifast With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
